Histone deacetylase inhibitors upregulate MMP11 gene expression through Sp1/Smad complexes in human colon adenocarcinoma cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 2, 2012, Pages 570-581

  Barrasa, Juan I ^a   Olmo, Nieves ^a   Santiago Gómez, Angélica ^a   Lecona, Emilio ^a   Anglard, Patrick ^b   Turnay, Javier ^a   Lizarbe, M Antonia ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Butyrate; Colon adenocarcinoma; Histone deacetylase inhibitor; MAP kinase; Metalloproteinase

Indexed keywords

BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; MITHRAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN SMAD PROTEIN COMPLEX; SMAD PROTEIN; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN 3; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CANCER CELL; CELL STRAIN BCS TC2; CELL STRAIN CACO 2; CELL STRAIN HT29; CHROMATIN IMMUNOPRECIPITATION; COLON ADENOCARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; SUPERSHIFT ASSAY; UPREGULATION;

ADENOCARCINOMA; BUTYRATES; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE 11; MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS, GENETIC; SMAD PROTEINS; SP1 TRANSCRIPTION FACTOR;

EID: 84855896774     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.12.010     Document Type: Article

References (58)

1. Folgueras A.R., Pendas A.M., Sánchez L.M., López-Otín C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. 2004, 48:411-424.
2. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006, 69:562-573.
3. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17:463-516.
4. Motrescu E.R., Blaise S., Etique N., Messaddeq N., Chenard M.P., Stoll I., Tomasetto C., Rio M.C. Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. Oncogene 2008, 27:6347-6355.
5. Luo D., Mari B., Stoll I., Anglard P. Alternative splicing and promoter usage generates an intracellular stromelysin 3 isoform directly translated as an active matrix metalloproteinase. J. Biol. Chem. 2002, 277:25527-25536.
6. Yan C., Boyd D.D. Regulation of matrix metalloproteinase gene expression. J. Cell. Physiol. 2007, 211:19-26.
7. Guérin E., Ludwig M.G., Basset P., Anglard P. Stromelysin-3 induction and interstitial collagenase repression by retinoic acid. Therapeutical implication of receptor-selective retinoids dissociating transactivation and AP-1-mediated transrepression. J. Biol. Chem. 1997, 272:11088-11095.
8. Basset P., Bellocq J.P., Wolf C., Stoll I., Hutin P., Limacher J.M., Podhajcer O.L., Chenard M.P., Rio M.C., Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990, 348:699-704.
9. Delebecq T.J., Porte H., Zerimech F., Copin M.C., Gouyer V., Dacquembronne E., Balduyck M., Wurtz A., Huet G. Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin. Cancer Res. 2000, 6:1086-1092.
10. Anderson I.C., Sugarbaker D.J., Ganju R.K., Tsarwhas D.G., Richards W.G., Sunday M., Kobzik L., Shipp M.A. Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res. 1995, 55:4120-4126.
11. Johnson L.D., Hunt D.M., Kim K., Nachtigal M. Amplification of stromelysin-3 transcripts from carcinomas of the colon. Hum. Pathol. 1996, 27:964-968.
12. Odaka C., Izumiyama S. Expression of stromelysin-3 (matrix metalloproteinase-11) in macrophages of murine thymus following thymocyte apoptosis. Cell. Immunol. 2005, 235:21-28.
13. Jia L., Wang S., Cao J., Zhou H., Wei W., Zhang J. siRNA targeted against matrix metalloproteinase 11 inhibits the metastatic capability of murine hepatocarcinoma cell Hca-F to lymph nodes. Int. J. Biochem. Cell Biol. 2007, 39:2049-2062.
14. Yang Y.H., Deng H., Li W.M., Zhang Q.Y., Hu X.T., Xiao B., Zhu H.H., Geng P.L., Lu Y.Y. Identification of matrix metalloproteinase 11 as a predictive tumor marker in serum based on gene expression profiling. Clin. Cancer Res. 2008, 14:74-81.
15. Ahmad A., Hanby A., Dublin E., Poulsom R., Smith P., Barnes D., Rubens R., Anglard P., Hart I. Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am. J. Pathol. 1998, 152:721-728.
16. Noel A., Boulay A., Kebers F., Kannan R., Hajitou A., Calberg-Bacq C.M., Basset P., Rio M.C., Foidart J.M. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 2000, 19:1605-1612.
17. Mari B.P., Anderson I.C., Mari S.E., Ning Y., Lutz Y., Kobzik L., Shipp M.A. Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J. Biol. Chem. 1998, 273:618-626.
18. Noel A.C., Lefebvre O., Maquoi E., VanHoorde L., Chenard M.P., Mareel M., Foidart J.M., Basset P., Rio M.C. Stromelysin-3 expression promotes tumor take in nude mice. J. Clin. Invest. 1996, 97:1924-1930.
19. Farrelly N., Lee Y.J., Oliver J., Dive C., Streuli C.H. Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J. Cell Biol. 1999, 144:1337-1348.
20. Wei L., Shi Y.B. Matrix metalloproteinase stromelysin-3 in development and pathogenesis. Histol. Histopathol. 2005, 20:177-185.
21. Navarro J.M., Olmo N., Turnay J., López-Conejo M.T., Lizarbe M.A. Differentiation of BCS-TC2 human colon adenocarcinoma cells by sodium butyrate: increase in 5'-nucleotidase activity. Eur. J. Clin. Invest. 1997, 27:620-628.
22. Olmo N., Turnay J., Pérez-Ramos P., Lecona E., Barrasa J.I., López de Silanes I., Lizarbe M.A. In vitro models for the study of the effect of butyrate on human colon adenocarcinoma cells. Toxicol. In Vitro 2007, 21:262-270.
23. Davie J.R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 2003, 133:2485S-2493S.
24. Lecona E., Barrasa J.I., Olmo N., Llorente B., Turnay J., Lizarbe M.A. Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase. Mol. Cell. Biol. 2008, 28:4665-4674.
25. Hammill D., Jain N., Armstrong S., Mueller C.R. The D-domain of Sp3 modulates its protein levels and activation of the p21(CIP1/WAF1) promoter. Biochem. Biophys. Res. Commun. 2005, 335:377-384.
26. Clark I.M., Swingler T.E., Young D.A. Acetylation in the regulation of metalloproteinase and tissue inhibitor of metalloproteinases gene expression. Front. Biosci. 2007, 12:528-535.
27. Turnay J., Olmo N., Gavilanes J.G., Benítez J., Lizarbe M.A. Establishment and characterization of a new human colon adenocarcinoma cell line: BCS-TC2. Cytotechnology 1990, 3:75-88.
28. López de Silanes I., Olmo N., Turnay J., González de Buitrago G., Pérez-Ramos P., Guzmán-Aránguez A., García-Díez M., Lecona E., Gorospe M., Lizarbe M.A. Acquisition of resistance to butyrate enhances survival after stress and induces malignancy of human colon carcinoma cells. Cancer Res. 2004, 64:4593-4600.
29. Anglard P., Melot T., Guérin E., Thomas G., Basset P. Structure and promoter characterization of the human stromelysin-3 gene. J. Biol. Chem. 1995, 270:20337-20344.
30. Luo D., Guerin E., Ludwig M.G., Stoll I., Basset P., Anglard P. Transcriptional induction of stromelysin-3 in mesodermal cells is mediated by an upstream CCAAT/enhancer-binding protein element associated with a DNase I-hypersensitive site. J. Biol. Chem. 1999, 274:37177-37185.
31. Okamoto T., Takahashi S., Nakamura E., Nagaya K., Hayashi T., Fujieda K. Transforming growth factor-beta1 induces matrix metalloproteinase-9 expression in human meningeal cells via ERK and Smad pathways. Biochem. Biophys. Res. Commun. 2009, 383:475-479.
32. Inoue Y., Itoh Y., Abe K., Okamoto T., Daitoku H., Fukamizu A., Onozaki K., Hayashi H. Smad3 is acetylated by p300/CBP to regulate its transactivation activity. Oncogene 2007, 26:500-508.
33. Schavinsky-Khrapunsky Y., Huleihel M., Aboud M., Torgeman A. Role of protein kinase C and the Sp1-p53 complex in activation of p21(WAF-1) expression by 12-O-tetradecanoylphorbol-13-acetate in human T cells. Oncogene 2003, 22:5315-5324.
34. Blume S.W., Snyder R.C., Ray R., Thomas S., Koller C.A., Miller D.M. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J. Clin. Invest. 1991, 88:1613-1621.
35. Thewes M., Pohlmann G., Atkinson M., Mueller J., Putz B., Hofler H. Stromelysin-3 (ST-3) mRNA expression in colorectal carcinomas. Localization and clinicopathologic correlations. Diagn. Mol. Pathol. 1996, 5:284-290.
36. Jungert K., Buck A., Buchholz M., Wagner M., Adler G., Gress T.M., Ellenrieder V. Smad-Sp1 complexes mediate TGFbeta-induced early transcription of oncogenic Smad7 in pancreatic cancer cells. Carcinogenesis 2006, 27:2392-2401.
37. Hung W.C., Chang H.C. Indole-3-carbinol inhibits Sp1-induced matrix metalloproteinase-2 expression to attenuate migration and invasion of breast cancer cells. J. Agric. Food Chem. 2009, 57:76-82.
38. Chen Y.J., Chang W.M., Liu Y.W., Lee C.Y., Jang Y.H., Kuo C.D., Liao H.F. A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. Chem. Biol. Interact. 2009, 181:440-446.
39. Sroka I.C., Nagle R.B., Bowden G.T. Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia 2007, 9:406-417.
40. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
41. Pavlaki M., Zucker S., Dufour A., Calabrese N., Bahou W., Cao J. Furin functions as a nonproteolytic chaperone for matrix metalloproteinase-28: MMP-28 propeptide sequence requirement. Biochem. Res. Int. 2011, 2011:630319.
42. Pei D., Weiss S.J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995, 375:244-247.
43. Barbacid M.M., Fernández-Resa P., Buesa J.M., Márquez G., Aracil M., Quesada A.R., Mira E. Expression and purification of human stromelysin 1 and 3 from baculovirus-infected insect cells. Protein Expr. Purif. 1998, 13:243-250.
44. Pulukuri S.M., Gorantla B., Rao J.S. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J. Biol. Chem. 2007, 282:35594-35603.
45. Pender S.L., Quinn J.J., Sanderson I.R., MacDonald T.T. Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279:G918-G924.
46. Emenaker N.J., Basson M.D. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation. J. Surg. Res. 1998, 76:41-46.
47. Lee J.C., Maa M.C., Yu H.S., Wang J.H., Yen C.K., Wang S.T., Chen Y.J., Liu Y., Jin Y.T., Leu T.H. Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells. Mol. Carcinog. 2005, 43:207-214.
48. Redondo-Muñoz J., Ugarte-Berzal E., Terol M.J., Van den Steen P.E., Hernández del Cerro M., Roderfeld M., Roeb E., Opdenakker G., García-Marco J.A., García-Pardo A. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010, 17:160-172.
49. Martin M.D., Matrisian L.M. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 2007, 26:717-724.
50. Decock J., Thirkettle S., Wagstaff L., Edwards D.R. Matrix metalloproteinases: protective roles in cancer. J. Cell. Mol. Med. 2011, 15:1254-1265.
51. Waby J.S., Chirakkal H., Yu C., Griffiths G.J., Benson R.S., Bingle C.D., Corfe B.M. Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol. Cancer 2010, 9:275.
52. Walker G.E., Wilson E.M., Powell D., Oh Y. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex. Endocrinology 2001, 142:3817-3827.
53. Huang W., Zhao S., Ammanamanchi S., Brattain M., Venkatasubbarao K., Freeman J.W. Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex. J. Biol. Chem. 2005, 280:10047-10054.
54. Lu N., Carracedo S., Ranta J., Heuchel R., Soininen R., Gullberg D. The human alpha11 integrin promoter drives fibroblast-restricted expression in vivo and is regulated by TGF-beta1 in a Smad- and Sp1-dependent manner. Matrix Biol. 2010, 29:166-176.
55. Tu A.W., Luo K. Acetylation of Smad2 by the co-activator p300 regulates activin and transforming growth factor beta response. J. Biol. Chem. 2007, 282:21187-21196.
56. Ammanamanchi S., Brattain M.G. Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells. J. Biol. Chem. 2004, 279:32620-32625.
57. Scharlau D., Borowicki A., Habermann N., Hofmann T., Klenow S., Miene C., Munjal U., Stein K., Glei M. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat. Res. 2009, 682:39-53.
58. Vincenti M.P., Brinckerhoff C.E. Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you?. J. Cell. Physiol. 2007, 213:355-364.